August 24, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval
Over 10 million Americans are afflicted with dry age-related macular degeneration (AMD), the leading cause of blindness. Worldwide, that number exceeds 150 million people.
InflammX has developed Xiflam, an orally administered small molecule which readily crosses the blood-retina barrier to treat ocular inflammation, the cause of AMD. The current standard of care requires monthly injections to the back of the eye. Adding insult to injury, the treatment is only 50% effective for those who get the shot. Even with these obvious limitations, this treatment generates $11.5 in revenue annually.
Xiflam, a once-a-day pill, is much more user-friendly and has shown reduced disease progression through a recent trial period.
Join our webinar with InflammX CEO, Dr. Brian Levy as he discusses how Xiflam is poised to disrupt this $11.5B industry.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.